FAE Stock Overview
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally.
Faes Farma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€3.91|
|52 Week High||€4.08|
|52 Week Low||€3.07|
|1 Month Change||-1.26%|
|3 Month Change||5.85%|
|1 Year Change||13.01%|
|3 Year Change||-5.67%|
|5 Year Change||34.36%|
|Change since IPO||242.17%|
Recent News & Updates
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Is Faes Farma (BME:FAE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will be increasing its dividend on the 23rd of December...
|FAE||ES Pharmaceuticals||ES Market|
Return vs Industry: FAE exceeded the Spanish Pharmaceuticals industry which returned 7.6% over the past year.
Return vs Market: FAE exceeded the Spanish Market which returned -11.2% over the past year.
|FAE Average Weekly Movement||3.3%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||3.7%|
|10% most volatile stocks in ES Market||6.9%|
|10% least volatile stocks in ES Market||1.3%|
Stable Share Price: FAE is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: FAE's weekly volatility (3%) has been stable over the past year.
About the Company
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
Faes Farma Fundamentals Summary
|FAE fundamental statistics|
Is FAE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FAE income statement (TTM)|
|Cost of Revenue||€159.28m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.29|
|Net Profit Margin||19.67%|
How did FAE perform over the long term?See historical performance and comparison
4.4%Current Dividend Yield
Does FAE pay a reliable dividends?See FAE dividend history and benchmarks
|Faes Farma dividend dates|
|Ex Dividend Date||Jun 28 2022|
|Dividend Pay Date||Jun 30 2022|
|Days until Ex dividend||3 days|
|Days until Dividend pay date||5 days|
Does FAE pay a reliable dividends?See FAE dividend history and benchmarks
Is FAE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FAE?
Other financial metrics that can be useful for relative valuation.
|What is FAE's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does FAE's PE Ratio compare to its peers?
|FAE PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the peer average (23.4x).
Price to Earnings Ratio vs Industry
How does FAE's PE Ratio compare vs other companies in the Pharmaceuticals Industry?
Price-To-Earnings vs Industry: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the European Pharmaceuticals industry average (18.2x)
Price to Earnings Ratio vs Fair Ratio
What is FAE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||13.6x|
|Fair PE Ratio||16x|
Price-To-Earnings vs Fair Ratio: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the estimated Fair Price-To-Earnings Ratio (16x).
Share Price vs Fair Value
What is the Fair Price of FAE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FAE (€3.91) is trading below our estimate of fair value (€6.62)
Significantly Below Fair Value: FAE is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: FAE is poor value based on its PEG Ratio (5.4x)
Discover undervalued companies
How is Faes Farma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FAE's forecast earnings growth (2.5% per year) is above the savings rate (0.9%).
Earnings vs Market: FAE's earnings (2.5% per year) are forecast to grow slower than the Spanish market (12.6% per year).
High Growth Earnings: FAE's earnings are forecast to grow, but not significantly.
Revenue vs Market: FAE's revenue (2.5% per year) is forecast to grow slower than the Spanish market (4.5% per year).
High Growth Revenue: FAE's revenue (2.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FAE's Return on Equity is forecast to be low in 3 years time (13%).
Discover growth companies
How has Faes Farma performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FAE has high quality earnings.
Growing Profit Margin: FAE's current net profit margins (19.7%) are higher than last year (18.6%).
Past Earnings Growth Analysis
Earnings Trend: FAE's earnings have grown by 16.5% per year over the past 5 years.
Accelerating Growth: FAE's earnings growth over the past year (20.6%) exceeds its 5-year average (16.5% per year).
Earnings vs Industry: FAE earnings growth over the past year (20.6%) exceeded the Pharmaceuticals industry 17.9%.
Return on Equity
High ROE: FAE's Return on Equity (16.4%) is considered low.
Discover strong past performing companies
How is Faes Farma's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: FAE's short term assets (€293.7M) exceed its short term liabilities (€79.3M).
Long Term Liabilities: FAE's short term assets (€293.7M) exceed its long term liabilities (€24.4M).
Debt to Equity History and Analysis
Debt Level: FAE has more cash than its total debt.
Reducing Debt: FAE's debt to equity ratio has increased from 0.2% to 4% over the past 5 years.
Debt Coverage: FAE's debt is well covered by operating cash flow (372.8%).
Interest Coverage: FAE's interest payments on its debt are well covered by EBIT (3460.7x coverage).
Discover healthy companies
What is Faes Farma current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: FAE's dividend (4.37%) is higher than the bottom 25% of dividend payers in the Spanish market (2.07%).
High Dividend: FAE's dividend (4.37%) is low compared to the top 25% of dividend payers in the Spanish market (6.06%).
Stability and Growth of Payments
Stable Dividend: FAE's dividend payments have been volatile in the past 10 years.
Growing Dividend: FAE's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (56.7%), FAE's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (258.9%), FAE's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Faes Farma has no CEO, or we have no data on them.
Experienced Board: FAE's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Faes Farma, S.A.'s employee growth, exchange listings and data sources
- Name: Faes Farma, S.A.
- Ticker: FAE
- Exchange: BME
- Founded: 1933
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €1.197b
- Shares outstanding: 306.24m
- Website: https://faesfarma.com
Number of Employees
- Faes Farma, S.A.
- Avenida Autonomía 10
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.